Collagenase clostridium histolyticum: Phase II started

BioSpecifics began an open-label, dose-escalation Phase II trial to evaluate single injections of 0.058, 0.15, 0.29 and 0.44 mg Xiaflex in about 14 lipoma patients. The product is approved in the U.S...